Published in Cell on April 22, 2005
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) (LAM) | NCT03062943
mTOR signaling in growth control and disease. Cell (2012) 29.21
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol (2009) 7.96
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev (2008) 4.52
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell (2006) 4.20
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol (2006) 3.11
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Regulation of TFEB and V-ATPases by mTORC1. EMBO J (2011) 2.84
The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. Mol Cell (2013) 2.79
A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J (2007) 2.69
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
Regulation of mTORC1 by amino acids. Trends Cell Biol (2014) 2.64
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
The tuberous sclerosis complex. Ann N Y Acad Sci (2010) 2.51
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
PPSP: prediction of PK-specific phosphorylation site with Bayesian decision theory. BMC Bioinformatics (2006) 2.34
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27
A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun (2014) 2.25
Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell (2011) 2.24
Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci (2013) 2.22
A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem (2009) 2.19
Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci (2010) 2.17
The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene (2009) 2.14
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A (2008) 2.04
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol (2007) 1.99
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) (2008) 1.95
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 1.93
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem (2010) 1.74
Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev (2011) 1.73
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 1.72
A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol (2009) 1.70
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe (2013) 1.69
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J Appl Physiol (1985) (2009) 1.65
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res (2014) 1.59
Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling. J Physiol (2011) 1.59
Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol (2009) 1.58
The cell biology of polycystic kidney disease. J Cell Biol (2010) 1.58
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol (2010) 1.58
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell (2016) 1.55
Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem (2009) 1.53
Regulation of protein synthesis by ionizing radiation. Mol Cell Biol (2009) 1.52
Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) (2009) 1.48
Exercise-induced alterations in extracellular signal-regulated kinase 1/2 and mammalian target of rapamycin (mTOR) signalling to regulatory mechanisms of mRNA translation in mouse muscle. J Physiol (2006) 1.48
BMAL1-dependent regulation of the mTOR signaling pathway delays aging. Aging (Albany NY) (2014) 1.48
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol (2006) 1.47
Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling. PLoS Biol (2013) 1.47
Negative regulation of mTOR activation by diacylglycerol kinases. Blood (2011) 1.46
Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med (2010) 1.46
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans. J Clin Invest (2008) 1.45
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene (2013) 1.40
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet (2009) 1.40
A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1. Mol Cell Biol (2009) 1.39
Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther (2011) 1.38
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle (2009) 1.38
From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res (2009) 1.37
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther (2008) 1.36
Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med (2013) 1.36
Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet (2010) 1.34
Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol (2014) 1.33
Identification of DOK genes as lung tumor suppressors. Nat Genet (2010) 1.32
L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission. Front Behav Neurosci (2011) 1.30
Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2005) 1.30
Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest (2010) 1.30
Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PLoS One (2012) 1.30
Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev (2012) 1.30
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev (2002) 13.08
PRDM16 controls a brown fat/skeletal muscle switch. Nature (2008) 13.08
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature (2007) 11.14
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Histone demethylation by a family of JmjC domain-containing proteins. Nature (2005) 10.36
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature (2008) 7.18
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell (2007) 5.78
Regulation of p53 activity through lysine methylation. Nature (2004) 5.78
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell (2002) 5.59
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev (2002) 5.43
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell (2004) 5.37
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell (2004) 5.06
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature (2011) 4.16
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell (2002) 4.08
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell (2005) 4.04
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol (2004) 3.90
Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev (2008) 3.90
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell (2002) 3.80
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70